May 2003
Volume 44, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2003
Evaluation of Potential Treatment Strategies for Leber Hereditary Optic Neuropathy
Author Affiliations & Notes
  • J. Guy
    Ophthalmology, University of Florida, Gainesville, FL, United States
  • X. Qi
    Ophthalmology, University of Florida, Gainesville, FL, United States
  • V. Carelli
    Neurology, University of Bologna, Bologna, Italy
  • A. Martinuzzi
    Neurology, E. Medea Scientific Institute, Conegliano, Italy
  • W.W. Hauswirth
    Neurology, E. Medea Scientific Institute, Conegliano, Italy
  • A.S. Lewin
    Neurology, E. Medea Scientific Institute, Conegliano, Italy
  • Footnotes
    Commercial Relationships  J. Guy, None; X. Qi, None; V. Carelli, None; A. Martinuzzi, None; W.W. Hauswirth, None; A.S. Lewin, None.
  • Footnotes
    Support  NIH EY 12355
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 941. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. Guy, X. Qi, V. Carelli, A. Martinuzzi, W.W. Hauswirth, A.S. Lewin; Evaluation of Potential Treatment Strategies for Leber Hereditary Optic Neuropathy . Invest. Ophthalmol. Vis. Sci. 2003;44(13):941.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose:To develop a treatment strategy for Leber Hereditary Optic Neuropathy (LHON) by rescue with complex II substrates or increasing cellular defenses against oxygen toxicity. Methods:To determine if complex II substrates that bypass the mutated complex I can be used to rescue LHON, cybrids cells were placed in glucose-free medium containing either the complex II substrate succinate or the complex I substrate pyruvate in addition to galactose as the main carbon source for glycolysis. This medium forces the cells to rely predominantly on oxidative phosphorylation to produce ATP. Cells harboring complex I mutations have a severe growth defect and die off in this galactose medium. In addition, to determine the role of oxygen toxicity in cell death we measured mitochondrial superoxide production using the florescent probe dihydroethidium. We evaluated the protective effect of increasing mitochondrial defenses against superoxide using adenoassociated virus (AAV) as a vector to deliver the human gene for mitochondrial superoxide dismutase (SOD2) to LHON cybrids. Results:After three days in the galactose medium containing the complex II substrate succinate, LHON cybrid cell populations dwindled 67%. This level of reduction was not significantly different than cells grown in the complex I substrate pyruvate that showed a 73% reduction. Relative to transmitochondrial LHON cybrids grown in glucose media, superoxide levels doubled in LHON cybrids placed in galactose media. Infection with AAV-expressing SOD2 increased cell survival in the galactose media, by 25%, relative to mock infection with AAV expressing GFP (p<0.008). Conclusions:We have shown here that administration of complex II substrates does not significantly improve LHON cybrid cell survival, thus suggesting that this approach may not be useful in the treatment of LHON. Moreover, despite the contribution of increased levels of superoxide to cell death and possibly optic neuropathy, the levels of antioxidant gene protection did not result in the threefold increases in cell survival that we previously reported using allotopic ND4 rescue, thus suggesting that other reactive oxygen species or reduced ATP synthesis may also play a role in cellular injury and optic neuropathy.

Keywords: mitochondria • gene transfer/gene therapy • neuro-ophthalmology: optic nerve 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×